$MYO

KIRK THOMAS F purchased $51K of MYO

KIRK THOMAS F purchased 40,002 shares of MYOMO, INC. (MYO) at $1.27 on 2026-06-05.

Original reporting
SEC EDGAR · KIRK THOMAS F
Published Jun 9, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MYO
Bullish
low confidence
Mentioned
$MYO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MYOBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (shares, price, and post-transaction holdings).

02

Market read

Provides a fresh insider-buy datapoint that may slightly influence sentiment, but lacks fundamental company catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; traders may still discount the signal because the disclosed dollar amount is relatively small versus typical institutional flows.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-09 (transaction dated 2026-06-05)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Myomo, Inc.

Company-level read

Ticker impact

$MYOBullishLow confidence
Context

Myomo director Kirk Thomas F filed an open-market purchase of 40,002 shares at $1.27 on 2026-06-05 (Form 4).

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

This is a Form 4 insider transaction with modest disclosed value (~$50.8k) and no accompanying company-specific operational or financial news.

Market effects

No clear sector read-through from a single small insider buy.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine diversification/compensation-related or driven by personal liquidity needs rather than a strong forward view.

Key entities

  • MYOMO, INC.

    Subject of the Form 4 insider transaction disclosure.

  • KIRK THOMAS F

    Director who purchased 40,002 shares open-market at $1.27 on 2026-06-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MYOMedAI 8/10

Myomo Q2 Earnings Call Highlights

Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.

$MYOHigh

MYOMO, INC. (MYO): Results of Operations and Financial Condition

MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guidance to $45-47 million Conference call beg

$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.